BeiGene goes for global growth with sales and R&D push
The maker of cancer drugs is ploughing most of its rising revenues into research and sales, as it prioritizes expansion over profits for now Key Takeaways: BeiGene’s revenue in the…
BGNE.US
6160.HK
Recent Articles
BeiGene goes for global growth with sales and R&D push
BGNE.US
6160.HK
RELATED ARTICLES
-
Heated market for dueling blood cancer drugs lands BeiGene in court
BGNE.US 6160.HK
-
Sales success comes with side effects for drug maker BeiGene
BGNE.US 6160.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
FAST NEWS: Beigene stock falls after Novartis terminates partnership
BGNE.US 6160.HK
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
CStone breaks up with drugs partner as U.S. rollout stalls
2616.HK
Discover hidden China stock gems in our weekly newsletter